Pancreatic

Pancreatic Cancer Has Genetic Early Warning System

Researchers have discovered how cellular stress and inflammation drive pancreatic cancer progression via the STAT3-ITGB3 pathway.

Pancreatic

AI-based Tool Offers Highly Accurate Pancreatic Cancer Diagnostics

A new deep learning model classifies pancreatic ductal adenocarcinoma into molecular subtypes using cost-effective histopathology images.

Pancreatic

Immunovia’s Pancreatic Cancer Test Up and Running at New Lab

Immunovia's new lab is now fully operational, marking a significant step towards enhancing early detection of pancreatic cancer.

PDACatch an FDA Breakthrough Device for Pancreatic Cancer Detection

May 8, 2023 | Pancreatic

Singlera Genomics’ PDACatch assay is a novel DNA methylation-based liquid biopsy assay for the detection of pancreatic adenocarcinoma in individuals at high risk for the disease.

Biomarkers Show Promise for Finding Pancreatic Cancer Risk Early

Mar 20, 2023 | Pancreatic

A research team identified biomarkers that could help distinguish whether cysts on the pancreas will develop into cancer or remain benign.

Bluestar Genomics Commercializes Pancreatic Cancer Test

Dec 21, 2022 | Pancreatic

Bluestar Genomics has announced its U.S. and international commercialization of a test for early detection of pancreatic cancer.

New Genetic Culprit Suspected of Pancreatic Cancer Onset

Dec 1, 2022 | Pancreatic

New research points to the inactivation of a previously unidentified gene as a likely culprit in the development of pancreatic cancer.

Bluestar Genomics’ Pancreatic Cancer Detection Test Achieves High Sensitivity & Specificity

Nov 2, 2022 | Pancreatic

Bluestar Genomics announced the results of a validation study for its early pancreatic cancer detection test.

Pancreatic Cancer Could be Diagnosed up to Three Years Earlier

Nov 1, 2022 | Pancreatic

Pancreatic cancer could be identified in patients up to three years earlier than current diagnoses, new research suggests.

Bluestar Genomics Receives CAP Accreditation for its Clinical Lab

Oct 10, 2022 | Accreditation, Pancreatic

The CAP certification enables Bluestar to serve physicians as it works towards broad commercialization of its pancreatic cancer test.

PancreaSeq Molecular Test Outperforms Current Guidelines

Oct 5, 2022 | Pancreatic, Sequencing Systems

The PancreaSeq molecular test accurately classifies pancreatic cysts as potentially cancerous or benign, a large, multi-center study found.

Personalis & BC Cancer Assess Benefits of ctDNA for Colorectal, Pancreatic Cancers

Aug 15, 2022 | Colorectal, Pancreatic

Personalis and BC Cancer will deploy a personalized liquid biopsy-based assay for a study of patients with colorectal and pancreatic cancers.

Researchers Discover Molecular Switch in Pancreatic Cancer that Triggers Metastasis

Jun 28, 2022 | Pancreatic

Pancreatic ductal adenocarcinoma affects more than 90% of patients with pancreatic cancer and has an average 5-year survival rate under 10%.

Stool Sample Microorganisms Could Help Detect Pancreatic Cancer Early

Mar 10, 2022 | Pancreatic

Researchers have found a molecular signature in stool samples that could predict whether patients are at high risk of pancreatic cancer.

Researchers May Have Found Diagnostic Game Changer for Pancreatic Cancer

Nov 17, 2021 | Pancreatic

Yale Cancer Center early detection research is providing new reason for optimism for the diagnosis of pancreatic cancer.

Liquid Biopsy Test Detects Pancreatic Cancer Signal

Nov 9, 2021 | Pancreatic

Bluestar Genomics’ liquid biopsy test can detect a pancreatic cancer signal in people across various age groups and in patients with new-onset diabetes.

Blood Test May Be Future of Pancreatic Cancer Detection

Oct 5, 2021 | Pancreatic

New research showed that blood tests may be the future of pancreatic cancer detection. Pancreatic cancer is one of the most deadly forms of the disease.